Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Ross

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Diagnostic Microbiology and Infectious Disease|November 17, 2009
Linezolid surveillance program results for 2008 (LEADER Program for 2008)David J Farrell, Rodrigo E Mendes, James E Ross, et al.
Diagnostic Microbiology and Infectious Disease|October 3, 2007
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|June 9, 2009
ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesRonald N Jones, Shigeru Kohno, Yasuo Ono, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2010
In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus sppDouglas J Biedenbach, James E Ross, Shannon D Putnam, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
Journal of Clinical Microbiology|April 25, 2014
Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agentJames E Ross, Nicole E Scangarella-Oman, Robert K Flamm, et al.
Journal of Clinical Microbiology|September 18, 2015
Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeaeStefan Riedel, James E Ross, David J Farrell, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Diagnostic Microbiology and Infectious Disease|November 17, 2009
Linezolid surveillance program results for 2008 (LEADER Program for 2008)David J Farrell, Rodrigo E Mendes, James E Ross, et al.
Diagnostic Microbiology and Infectious Disease|October 3, 2007
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|June 9, 2009
ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesRonald N Jones, Shigeru Kohno, Yasuo Ono, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2010
In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus sppDouglas J Biedenbach, James E Ross, Shannon D Putnam, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
Journal of Clinical Microbiology|April 25, 2014
Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agentJames E Ross, Nicole E Scangarella-Oman, Robert K Flamm, et al.
Journal of Clinical Microbiology|September 18, 2015
Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeaeStefan Riedel, James E Ross, David J Farrell, et al.
Pageof 4